Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holger Fischer

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 25, 2009
Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitorsMarkus Boehringer, Holger Fischer, Michael Hennig, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 InhibitorsEmmanuel Pinard, Daniela Alberati, Ruben Alvarez-Sanchez, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
An aminomethylpyrimidine DPP-IV inhibitor with improved propertiesJens-Uwe Peters, Daniel Hunziker, Holger Fischer, et al.
Clinical Therapeutics|April 26, 2024
Lessons Learned From Clinical Studies in Centronuclear Myopathies: The Patient Perspective-A Qualitative StudyLizan Stinissen, Johann Böhm, Sietse Bouma, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Neuromuscular Disorders : NMD|January 30, 2024
The experience of clinical study and trial participation in rare diseases: A scoping review of centronuclear myopathy and other neuromuscular disordersLizan Stinissen, Sietse Bouma, Johann Böhm, et al.
Chemmedchem|May 29, 2007
Predicting and tuning physicochemical properties in lead optimization: amine basicitiesMartin Morgenthaler, Eliane Schweizer, Anja Hoffmann-Röder, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2009
Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesPatrizio Mattei, Markus Boehringer, Patrick Di Giorgio, et al.
Biological Psychiatry Global Open Science|January 20, 2025
Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Male MiceWei-Li Chang, Karly Tegang, Benjamin A Samuels, et al.
The Breast Journal|April 7, 2019
Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohortKerstin Rhiem, Hans-Joachim Bücker-Nott, Martin Hellmich, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|December 25, 2009
Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitorsMarkus Boehringer, Holger Fischer, Michael Hennig, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 InhibitorsEmmanuel Pinard, Daniela Alberati, Ruben Alvarez-Sanchez, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
An aminomethylpyrimidine DPP-IV inhibitor with improved propertiesJens-Uwe Peters, Daniel Hunziker, Holger Fischer, et al.
Clinical Therapeutics|April 26, 2024
Lessons Learned From Clinical Studies in Centronuclear Myopathies: The Patient Perspective-A Qualitative StudyLizan Stinissen, Johann Böhm, Sietse Bouma, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Neuromuscular Disorders : NMD|January 30, 2024
The experience of clinical study and trial participation in rare diseases: A scoping review of centronuclear myopathy and other neuromuscular disordersLizan Stinissen, Sietse Bouma, Johann Böhm, et al.
Chemmedchem|May 29, 2007
Predicting and tuning physicochemical properties in lead optimization: amine basicitiesMartin Morgenthaler, Eliane Schweizer, Anja Hoffmann-Röder, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2009
Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesPatrizio Mattei, Markus Boehringer, Patrick Di Giorgio, et al.
Biological Psychiatry Global Open Science|January 20, 2025
Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Male MiceWei-Li Chang, Karly Tegang, Benjamin A Samuels, et al.
The Breast Journal|April 7, 2019
Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohortKerstin Rhiem, Hans-Joachim Bücker-Nott, Martin Hellmich, et al.
Pageof 7